

Original article

A randomized controlled trial of Promoting Physical Activity in Regional and Remote Cancer Survivors (PPARCS)

Sarah J Hardcastle <sup>a,b,c,\*</sup>, Chloe Maxwell-Smith <sup>c</sup>, Vinicius Cavalheri <sup>d,e</sup>, Terry Boyle <sup>f</sup>, Marta Leyton Román <sup>g</sup>, Cameron Platell <sup>h</sup>, Michael Levitt <sup>h</sup>, Christobel Saunders <sup>h,i</sup>, Frank Sardelic <sup>j</sup>, Sophie Nightingale <sup>j</sup>, Jacob McCormick <sup>k</sup>, Craig Lynch <sup>l</sup>, Paul A. Cohen <sup>b,h,m</sup>, Max Bulsara <sup>b</sup>, Dana Hince <sup>b</sup>

<sup>a</sup> Sport and Physical Activity Research Centre, Sheffield Hallam University, Sheffield, S10 2BP, UK

<sup>b</sup> Institute for Health Research, The University of Notre Dame, Fremantle, WA 6959, Australia

<sup>c</sup> Curtin School of Population Health, Curtin University, Perth, WA 6845, Australia

<sup>d</sup> Curtin School of Allied Health, Curtin University, Perth, WA 6845, Australia

<sup>e</sup> Allied Health, South Metropolitan Health Service, Murdoch, WA 6150, Australia

<sup>f</sup> Australian Centre for Precision Health, University of South Australia, Adelaide, SA 5001, Australia

<sup>g</sup> Department of Didactics of Musical, Plastic and Body Expression, University of Extremadura, Caceres 10071, Spain

<sup>h</sup> St. John of God Subiaco Hospital, Perth, WA 6008, Australia

<sup>l</sup> Department of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia

<sup>j</sup>Tamara Private Hospital, Tamworth, NSW 2340, Australia

<sup>k</sup>Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia

<sup>l</sup>College of Health and Medicine, Australian National University, Canberra, ACT 2600,  
Australia

<sup>m</sup>Division of Obstetrics and Gynaecology, Medical School, University of Western Australia,  
Perth, WA 6009, Australia

\* Corresponding author.

Email address: Sarah.Hardcastle@shu.ac.uk

---

Running title: PPARCS trial to promote PA in cancer survivors

**Supplementary Tables**

Supplementary Table 1. Estimated between arm (net mean difference) and within arm (T2–T1) mean differences (95%CI) for MVPA and secondary ActiGraph activity outcomes for completers (data available for both T1 and T2), protocol adherers (completed 4 or more health-coaching sessions), and insufficiently active participants (<150 min/week MVPA from ActiGraph at T1).

	Intervention change–Control change (T2)		Arm x Time interaction		Intervention change (T2–T1)		Control change (T2–T1)	
	Net mean difference	95%CI	$\chi^2(1)^1$	p	Mean difference	95%CI	Mean difference	95%CI
<b>COMPLETERS (n = 72)</b>								
MVPA (min/week)	45.1	8.3 to 81.9	5.77	<b>0.016</b>	64.7	37.0 to 92.5	19.6	–4.5 to 43.8
MV10	38.0	10.0 to 66.0	7.08	<b>0.008</b>	48.2	25.5 to 71.0	10.2	–5.4 to 28.8
Moderate PA (min/week)	44.5	7.5 to 81.5	5.56	<b>0.018</b>	60.7	32.7 to 88.6	16.1	–8.1 to 40.4
Light (min/week)	–2.2	–177.7 to 173.3	0.00	0.980	131.6	–0.8 to 264.1	133.9	18.7 to 249.0
Sedentary time (min/week)	–49.0	–256.5 to 158.4	0.21	0.643	–184.1	–340.7 to –27.5	–135.1	–271.3 to 1.07
Sedentary  ≥20–min bouts (h/week)	–37.8	–255.9 to 180.3	0.12	0.734	–54.7	–219.3 to 109.9	–16.9	–160.0 to 126.2
<b>PROTOCOL ADHERERS</b>								

**(n = 80)**

MVPA (min/week)	47.8	11.3 to 84.3	6.6	<b>0.010</b>	66.7	39.2 to 94.2	18.9	-5.1 to 42.9
MV10	37.9	9.9 to 65.8	7.1	<b>0.008</b>	48.2	24.5 to 71.9	10.3	-5.5 to 26.2
Moderate PA (min/week)	47.4	10.6 to 84.1	6.4	<b>0.012</b>	62.7	35.1 to 90.3	15.3	-8.8 to 39.5
Light (min/week)	11.8	-162.9 to 186.4	0.02	0.895	139.8	8.3 to 271.4	128.1	13.2 to 242.9
Sedentary time (min/week)	-54.7	-261.4 to 152.0	0.27	0.604	-184.1	-339.8 to -28.5	-129.4	-265.4 to 6.6
Sedentary ≥20-min bouts (h/week)	-42.4	-259.4 to 174.6	0.15	0.702	-51.9	-215 to 111.5	-9.6	-152.4 to 133.3

**INSUFFICIENTLY****ACTIVE (n = 54)**

MVPA (min/week)	30.4	-4.2 to 65.0	2.96	0.085	61.0	34.3 to 87.6	30.6	8.5 to 52.7
MV10	31.9	-3.5 to 67.3	3.12	0.078	47.5	18.4 to 76.7	15.6	-4.4 to 35.6
Moderate PA (min/week)	22.5	-9.5 to 54.6	1.90	0.168	52.7	28.0 to 77.4	30.1	9.7 to 50.6
Light (min/week)	-84.9	-287.0 to 117.2	0.68	0.411	98.4	-59.3 to 256.1	183.3	56.9 to 309.7
Sedentary time (min/week)	44.6	-210.6 to 299.8	0.12	0.732	-124.8	-323.4 to 73.9	-169.4	-329.5 to -9.2

Sedentary	-9.2	-319.6 to 301.2	0.00	0.954	6.3	-234.9 to 247.5	15.5	-179.8 to 210.9
-----------	------	-----------------	------	-------	-----	-----------------	------	-----------------

≥20-min bouts (h/week)

---

Mean differences are estimated from the mixed model.

<sup>1</sup>Wald  $\chi^2$  test for the Arm x Time interaction.

Abbreviations: 95%CI = 95% confidence interval; MV10 = minutes of moderate-to-vigorous physical activity completed in bouts of at least 10 min MVPA = moderate-to-vigorous physical activity; PA = physical activity. T1= Baseline ; T2 = 12-weeks following baseline.

Supplementary Table 2. Estimated between arm (net mean difference) and within arm (T2–T1) mean differences (95% CI) for ActiGraph-derived outcomes following adjustments for sex, cancer type, ActiGraph wear-time, age, comorbidity index, and remoteness classification (inner rural vs. other).

	Covariate	Intervention change–Control change (T2)		Arm x Time interaction <sup>1</sup>		Intervention change (T2–T1)		Control change (T2–T1)	
		Adjusted net difference	95%CI	$\chi^2(1)$	<i>p</i>	Adjusted mean difference	95%CI	Adjusted mean difference	95%CI
<b>MVPA</b>									
(min/week)	Sex	49.8	13.5 to 86.0	7.25	<b>0.007</b>	68.6	41.4 to 95.8	18.8	–5.1 to 42.8
	Cancer type	50.2	14.0 to 86.5	7.37	<b>0.007</b>	68.9	41.7 to 96.2	18.7	–5.3 to 42.9
	Wear-time (min)	49.3	13.0 to 85.7	7.07	<b>0.008</b>	67.7	40.4 to 95.0	18.4	–5.7 to 42.4
	Age	49.9	13.7 to 86.1	7.31	<b>0.007</b>	69.6	42.4 to 96.7	19.6	–4.3 to 43.6
	Comorbidity index	48.3	12.1 to 84.4	6.85	<b>0.009</b>	67.5	40.4 to 94.6	19.2	–4.7 to 43.1
	Remoteness	45.7	9.6 to 81.9	6.17	<b>0.013</b>	64.6	37.4 to 91.9	18.9	–4.8 to 42.6
<b>MV10</b>									
(min/week)	Sex	39.7	12.1 to 67.2	8.0	<b>0.005</b>	50.1	27.9 to 72.3	10.4	–5.3 to 26.2
	Cancer type	40.2	12.6 to 67.8	8.2	<b>0.004</b>	50.3	28.1 to 72.4	10.1	–5.6 to 25.8
	Wear-time (min)	38.0	10.8 to 65.3	7.5	<b>0.006</b>	48.1	26.5 to 69.8	10.1	–5.9 to 26.1
	Age	38.8	11.4 to 66.3	7.7	<b>0.006</b>	50.1	28.1 to 72.1	11.3	–4.6 to 27.1
	Comorbidity index	38.7	11.2 to 66.2	7.6	<b>0.006</b>	49.2	27.1 to 71.4	10.5	–5.2 to 26.2
	Remoteness	43.4	17.0 to 69.8	10.4	<b>0.001</b>	53.9	32.0 to 75.8	10.5	–4.5 to 25.4
<b>Moderate PA</b>									
(min/week)	Sex	49.4	13.0 to 85.8	7.07	<b>0.008</b>	64.7	37.4 to 92.0	15.3	–8.8 to 39.4
	Cancer type	49.8	13.4 to 86.3	7.18	<b>0.007</b>	65.0	37.7 to 92.3	15.2	–8.9 to 39.3
	Wear-time (min)	49.0	12.4 to 85.6	6.89	<b>0.009</b>	63.9	36.4 to 91.4	14.9	–9.3 to 39.1
	Age	49.5	13.1 to 85.9	7.12	<b>0.008</b>	65.6	38.4 to 92.8	16.1	–8.0 to 40.2
	Comorbidity index	47.9	11.6 to 84.2	6.68	<b>0.010</b>	63.6	36.4 to 90.8	15.7	–8.3 to 39.7
	Remoteness	43.6	7.9 to 79.3	5.74	<b>0.017</b>	59.0	32.1 to 85.9	15.4	–8.0 to 38.8

Light PA									
(min/week)	Sex	34.4	-140.0 to 208.8	0.15	0.699	163.3	32.3 to 294.2	128.8	13.7 to 244.0
	Cancer type	29.3	-145.0 to 203.5	0.11	0.742	158.2	27.3 to 289.0	128.9	13.9 to 244.0
	Wear-time (min)	23.5	-140.1 to 187.1	0.08	0.778	143.9	21.0 to 266.9	120.4	12.4 to 228.5
	Age	31.0	-143.5 to 205.5	0.12	0.728	161.1	30.1 to 292.1	130.1	14.8 to 245.4
	Comorbidity index	25.6	-148.2 to 199.4	0.08	0.773	154.9	24.4 to 285.4	129.3	14.5 to 244.1
	Remoteness	9.7	-163.9 to 183.3	0.01	0.913	138.4	7.1 to 269.8	128.7	15.1 to 242.3
Sedentary time									
(min/week)	Sex	-68.7	-274 to 136.9	0.43	0.512	-199.2	-353.3 to -45.1	-130.5	-266.6 to 5.6
	Cancer type	-62.7	-268.5 to 143.0	0.36	0.550	-193.1	-347.4 to -38.9	-130.4	-266.6 to 5.7
	Wear-time (min)	-71.6	-246.9 to 103.8	0.64	0.424	-210.7	-342.5 to -78.9	-139.1	-254.9 to -23.3
	Age	-63.0	-268.3 to 142.3	0.36	0.548	-195.4	-349.3 to -41.6	-132.4	-268.4 to 3.5
	Comorbidity index	-56.0	-260.9 to 148.8	0.29	0.591	-187.3	-340.8 to -33.7	-131.2	-266.7 to 4.3
	Remoteness	-28.0	-227.6 to 171.5	0.08	0.783	-158.0	-308.8 to -7.3	-130.0	-260.8 to 0.7
Sedentary ≥20-min bouts									
(min/week)	Sex	-62.0	-278.4 to 154.4	0.32	0.575	-72.9	-235.1 to 89.3	-10.9	-154.3 to 132.4
	Cancer type	-52.1	-268.7 to 164.4	0.22	0.637	-63.2	-225.5 to 99.1	-11.1	-154.4 to 132.2
	Wear-time (min)	-58.7	-266.9 to 149.5	0.31	0.581	-72.3	-228.7 to 84.2	-13.6	-151.2 to 124.1
	Age	-53.5	-270.1 to 163.1	0.23	0.628	-66.8	-229.1 to 95.5	-13.3	-156.8 to 130.2
	Comorbidity index	-44.5	-259 to 170.9	0.16	0.685	-56.3	-217.7 to 105.2	-11.7	-154.2 to 130.8
	Remoteness	-25.2	-238.8 to 188.3	0.05	0.817	-35.7	-197.0 to 125.6	-10.5	-150.4 to 129.4

Months since diagnosis was not included due to missing data for this variable. Mean differences are estimated from the mixed model.

<sup>1</sup> Wald  $\chi^2$  test for the Arm x Time interaction.

Abbreviations: 95%CI = 95% confidence interval; MV10 = minutes of moderate-to-vigorous physical activity completed in bouts of at least 10 minutes MVPA = moderate-to-vigorous physical activity; PA = physical activity. T1= Baseline ; T2 = 12-weeks following baseline .

